Thursday, May 18, 2023

May 18, 2023: Johns Hopkins COVID 19 Situation Report

COVID-19 Situation Report

Weekly updates on COVID-19 epidemiology, science, policy, and other news you can use.

Click to Subscribe

In this issue

> COVID-19 pandemic continues despite end of WHO, US emergency declarations; world must take actions on lessons learned to prepare for next disease emergency

> US CDC building ventilation guidance, ASHRAE draft standard for control of infectious aerosols represent important public health achievements, experts say

> Debate over masking in healthcare settings continues, with more evidence provided by new review in Annals of Internal Medicine

> What we're reading

> Epi update

COVID-19 pandemic continues despite end of WHO, US emergency declarations; world must take actions on lessons learned to prepare for next disease emergency

On May 5, WHO Director-General Dr. Tedros Adhanom Ghebreyesus declared that the COVID-19 pandemic no longer constitutes a public health emergency of international concern (PHEIC) as defined under the International Health Regulations (IHR). In its 15th meeting, the IHR Emergency Committee for COVID-19 agreed that the pandemic no longer represents an “extraordinary event,” as all nations are now used to dealing with the virus, though not all are equally equipped to do so. With this change in designation, the WHO now recommends that all nations shift into long-term management of the pandemic. Additionally, the US public health emergency (PHE) for COVID-19 expired on May 11, 3 years and 100 days after the Trump administration first made the declaration.

It is easy to misinterpret WHO’s removal of the PHEIC designation and the end of the US PHE as an end to the pandemic, accompanied by a return to normalcy. However, SARS-CoV-2 continues to circulate and cause thousands of cases of COVID-19 per day. According to the US CDC, more than 1,000 people die each from COVID-19–related complications. While the overt signs of daily life disruptions and mitigation measures have ended, such as lockdowns and mask mandates, many still find their lives uprooted due to the loss of loved ones, struggles with long COVID, or continuous efforts to protect themselves or their friends and family who are at higher risk of severe disease from infection. Those in the US who were most vulnerable at the beginning of the pandemic remain so but now have access to fewer resources and programs for assistance, as federal pandemic funding runs out. Policymakers and public health officials must remain cognizant to not leave behind those most vulnerable and to better prepare for future SARS-CoV-2 variants or a new pandemic.

Additionally, global economies continue to experience the fallout from the pandemic, though some are recovering faster than others. The UN Department of Economic and Social Affairs projects that the global economy will grow by 2.3% in 2023 and 2.5% in 2024, well below the average growth rate of 3.1% in the 2 decades prior to COVID-19. In particular, the Africa region and the Latin America and Caribbean region are experiencing the least economic growth, falling well below growth targets set in the 2030 Agenda for Sustainable Development. In addition to dealing with supply chain issues, recent estimates suggest that about 10% of people infected with SARS-CoV-2 go on to develop long COVID, decreasing workforce functionality. As the world settles into this new global context, it is the responsibility of governments to maintain vigilance against the ongoing pandemic and to invest in preparedness to help avoid catastrophic outcomes in future disease outbreaks. Work is underway—and must continue—to evaluate response efforts and act on lessons learned so governments, institutions, and international organizations can prevent the cycle of neglect the world has experienced in past interpandemic periods.

US CDC building ventilation guidance, ASHRAE draft standard for control of infectious aerosols represent important public health achievements, experts say

The US CDC last week published updated guidance for building ventilation to help prevent indoor transmission of airborne viral particles, including recommendations for a goal of 5 air changes per hour and upgrading to MERV-13 air filters. The document represents the first time a federal agency has included a target for how much rooms and buildings should be ventilated to help reduce the risk of disease transmission. The recommendations also include suggestions to keep fans in the “on” versus “auto” position, adding fresh air when possible, using appropriately sized air cleaners, installing ultraviolet air treatment systems, and using carbon dioxide monitoring systems.

Additionally, ASHRAE—a professional society of building mechanical engineers that sets building energy and ventilation standards, among other standards and guidelines—this week released a first draft of its standard for maintaining healthy indoor air quality (IAQ), ASHRAE Standard 241P, Control of Infectious Aerosols. The standard provides minimum requirements for HVAC-related measures to reduce the risk of transmission of SARS-CoV-2, influenza, and other airborne viruses in homes, offices, schools, hospitals, and other buildings during periods of high risk. A public comment period runs through May 26, with publication expected in July.

IAQ experts lauded the release of both the CDC guidance and the ASHRAE standard, with some saying the developments could represent the beginning of an IAQ “revolution” and are among the most important public health achievements of the 21st century. Because most buildings in the US were constructed to meet minimal air quality standards, before much was known about how to mitigate indoor respiratory disease transmission, the recommended improvements will go a long way toward not only reducing disease spread but also help reduce asthma exacerbations and allergy symptoms and improve cognitive functioning for people working and studying in buildings that follow the new standards.

Debate over masking in healthcare settings continues, with more evidence provided by new review in Annals of Internal Medicine

Mask use in healthcare settingsremains a highly politicized and divisive topic. Continuing mask use in healthcare settings such as hospitals could help tocurb transmission of respiratory viral diseases between patients and staff. Not only could it reduce occupational exposure to COVID-19 for healthcare personnel, but it also could protect patients—particularly those who are immunocompromised—in cases where healthcare personnel with respiratory infections feel pressured to come to work when sick. Masking remains one ofthe last lines of protection against COVID-19 for medically vulnerable patients.

However, substantial gaps remain about whether masks work to prevent SARS-CoV-2 infections in healthcare settings and under what conditions.A recent review published in the Annals of Internal Medicine adds to the evidence base around whether masks are protective against SARS-CoV-2 infection in healthcare and community settings, an approach that differs from a recently published Cochrane review that examined studies of various physical interventions, including masks, to reduce viral respiratory illness in general. The Annals study found that mask use may be associated with a small reduction in risk of SARS-CoV-2 infection in community settings and that surgical masks and N95 respirators may be associated with similar infection risk in routine patient care settings, though the researchers did not rule out the beneficial effects of N95 respirators.

The authors ofan accompanying commentary recommend that despite the lack of gold-standard evidence about whether masks are protective in healthcare settings, mask use for patient and healthcare personnel interactions should be considered a safety measure, as with the widely accepted practice of hand hygiene.In an editorial, Annals of Internal Medicine editors note that studying the effectiveness of masks to prevent passage of a virus or to prevent SARS-CoV-2 infection is different from studying the effectiveness of masks themselves or of masking recommendations or policies. Whether policies move forward with mask-optional or mask-required approaches, experts agree that mask use should be only one element of a multicomponent strategy to reduce respiratory disease transmission in healthcare or other settings.

What we’re reading

US GAO REPORT A US Government Accountability Office (GAO) report released last week highlights persistent deficiencies of the US Department of Health and Human Services (HHS) in its ability to lead preparedness and response efforts for public health emergencies. The 13-page report calls out 5 areas where HHS has consistently fallen short, including developing clear roles and responsibilities; establishing a network to collect and analyze complete and consistent data; providing clear and consistent communication; establishing transparency and accountability; and working to understand key partners’ capabilities and limitations. The report notes that 91 of 155 GAO recommendations to HHS since 2007 remain outstanding as of April 2023 and calls on the executive branch and US Congress to urgently provide leadership and attention to ensure the nation is prepared to manage multiple simultaneous threats, mitigate their economic impact, and aid in recovery.

US SENATE COVID-19 ORIGIN REPORT US Senator Marco Rubio (R-FL), vice chair of the Senate Intelligence Committee, this week published a report based on a nearly 2-year investigation into the origins of the COVID-19 pandemic that presents circumstantial evidence his office says supports the theory that the novel coronavirus likely escaped from a lab in Wuhan, China. The report acknowledges that the probe did not find a “smoking gun” to prove the virus emerged from a lab incident rather than arose naturally, although the report suggests there was some sort of serious biocontainment failure or accident at the Wuhan Institute of Virology during the latter half of 2019. Various intelligence agencies remain split on the virus’s origin. Under the COVID-19 Origin Act of 2023, which US President Joe Biden signed on March 20, the director of national intelligence has until June 18—90 days—to declassify information about the Wuhan lab’s research and activities related to the pandemic, including details about any researchers who fell ill in the fall of 2019.

INFECTIOUS DISEASE EXPERTS' CONTRIBUTIONS In an interview with Healio, Dr. Amesh Adalja, senior scholar with the Johns Hopkins Center for Health Security, discusses a recent research article published in the journal Clinical Infectious Diseases, in which he and colleagues wrote about the contributions of infectious disease specialists in helping to mitigate the impacts of COVID-19, from treating patients to improving understanding of the new disease. The paper is based on a larger report published in August 2022. The authors noted that infectious disease experts made “diverse and unique contributions that went well beyond their usual responsibilities”—often without additional compensation—such as helping to reopen schools, workplaces, and entertainment venues. In the interview, Dr. Adalja notes those efforts were core to the resiliency and recovery of many communities and organizations and says policy changes, such as medical school debt relief and increased compensation, could help to fortify the infectious disease workforce for future pandemics.

J&J-JANSSEN VACCINE The J&J-Janssen COVID-19 vaccine is no longer available in the United States, according to an announcement from the US CDC. The last remaining stockpiles of the vaccine expired on May 7, and the agency said any remaining shots should be disposed of in accordance with local, state, and federal regulations. More than 31.5 million doses of the vaccine were delivered to states and territories, but only about 19 million people received the vaccine, representing about 7% of vaccinated US residents.

ACCESS TO MEDICAL OXYGEN The COVID-19 pandemic highlighted the longstanding problem of unequal access to medical oxygen in low- and middle-income countries (LMICs), where demand surged but supply fell short, Devex reports. Advocates are now urging the gas industry, especially the 6 major companies producing medical liquid oxygen (LOX), to ensure sustainable access to LMICs. Before the pandemic, the industry’s focus was more on industrial gasses and not medical products, and LOX sales were mainly to high-income countries. The industry's lack of investment in production facilities in LMICs and a lack of demand from those countries exacerbated the crisis. In a recent report, the Access to Medicine Foundation proposed 6 steps to improve access to LOX in LMICs over the next several years, including industrywide strategies, equitable pricing, expanded production capacity, and collaboration with governments and donors. The World Health Assembly also is considering a WHO resolution to address the issue.

“THE BAT LANDS” In the first of a graphically rich 5-part series, Reuters examines areas of the world where bat habitat is being threatened by agriculture, extractive industries, infrastructure, and other development, creating “jump zones” where there is an increased risk of a bat-borne pathogen spilling over to the human population. According to the analysis, these areas cover 6% of Earth’s land mass, and more than 1 of every 5 people on the planet lives in an area at highest risk of bat disease zoonosis. The other 4 parts examine the spread of the Nipah virus, how China’s efforts to expand its economic reach are driving deforestation and increasing the risk of bat zoonotic diseases, research into bats and their habitats in the vast Amazon rainforest, and efforts to manage bat-human interactions and invest in more monitoring and preparedness.

Epi update

As of May 17, the WHO COVID-19 Dashboard reports:

  • 766.4 million cumulative COVID-19 cases
  • 6.9 million deaths
  • 546,435 million cases reported week of May 8
  • 11% decrease in global weekly incidence
  • 4,266 deaths reported week of May 8
  • 9% increase in global weekly mortality

Over the previous week, case incidence declined or remained relatively stable in all WHO regions. The increase in deaths is attributable primarily to a 49% weekly increase in the Americas, which could be the result of a reporting backlog.

UNITED STATES

When the US public health emergency for SARS-CoV-2 expired on May 11, so too did the US CDC’s authorizations to collect certain public health data. Though COVID-19 remains a public health priority, the CDC will use COVID-19–associated hospital admission levels and the percentage of all COVID-19–associated deaths as the primary surveillance indicators. As such, the CDC COVID Data Tracker has been redesigned and most remaining data will be updated on a weekly basis.

The US CDC is reporting:

  • 1.13 million deaths (decrease of 5.3% in past week)
  • 9,456 weekly COVID-19 hospital admissions as of May 6 (decrease of 6.5%)

The Omicron sublineages XBB.1.5 (64%), XBB.1.16 (14%), XBB.1.9.1 (9%), XBB.1.9.2 (4%), XBB.2.3 (3.5%), XBB.1.5.1 (2.4%), and FD.2 (1.8%) currently account for a majority of all new sequenced specimens, with various other Omicron subvariants accounting for the remainder of cases.

Editor: Alyson Browett, MPH

Contributors: Erin Fink, MS; Clint Haines, MS; Amanda Kobokovich, MPH; Aishwarya Nagar, MPH; Christina Potter, MSPH; Matthew Shearer, MPH; and Rachel A. Vahey, MHS

Tuesday, May 9, 2023

DANGER in Rockford


WKSC 103.5 KISS FM

One Illinois City Ranks Among The 'Most Dangerous' In The US

By Logan DeLoye,

18 hours ago

https://img.particlenews.com/image.php?url=1Hg17A_0mHjul4M00Photo: iStockphoto

When you think of the most dangerous cities across the country, which come to mind? Perhaps larger cities such as New York, New York Los Angeles, California, and Chicago, Illinois due to their population size, but this is not always the case. In fact, none of the cities mentioned above even made the list of the most dangerous cities across the country. Dangerous rankings in each city were determined by the number of murders and property-related crimes that occurred between 2022 and 2023.

According to a list compiled by U.S. News & World Report , the most dangerous city in all of Illinois is Rockford. This city also ranks among the top 25 most dangerous cities in America.

Here is what U.S. News & World Report had to say about the most dangerous city in Illinois :

"Rockford’s economy has long relied on manufacturing, but its major industries have evolved over time. In the 1920s, Rockford was one of the country’s largest makers of furniture. Then, it became the nation’s top producer of fasteners, earning it the nickname Screw Capital of the World. Today, Rockford’s economy is tied tightly to the aerospace industry. It also has three large hospital systems and serves as a logistics hub, with a large cargo airport and access to Interstate 90."

For a continued list of the most dangerous cities across the country visit realestate.usnews.com .

Thursday, May 4, 2023

May 4, 2023: Johns Hopkins COVID 19 Situation Report

COVID-19 Situation Report

Weekly updates on COVID-19 epidemiology, science, policy, and other news you can use.

Click to Subscribe

Announcements

PUBLISHING NOTICE The COVID-19 Situation Report will be taking a break next week and will not be published on May 11. We will resume publishing on May 18.

In this issue

> Surveillance efforts decline as US prepares to wind down public health emergency; WHO panel meets to discuss whether to continue PHEIC

> Experts begin to assess pandemic responses, glean lessons learned to prepare for next pandemic

> Journal articles review progress made, lessons learned on COVID-19 treatment; studies into new treatments, repurposed drugs continue

> Vaccine effectiveness studies support use of bivalent formulations, show monovalent vaccines highly effective against severe disease, death but effectiveness waned quickly against Omicron

> Decreasing US racial disparities in COVID-19 deaths possibly due to more deaths among Whites, study shows

> What we're reading

> Epi update

Surveillance efforts decline as US prepares to wind down public health emergency; WHO panel meets to discuss whether to continue PHEIC

As the COVID-19 pandemic enters its fourth year, surveillance of the disease has declined dramatically, both in the US and internationally. The US public health emergency is set to expire on May 11—bringing an end to most federal COVID-19 vaccine requirements—and the US CDC plans to stop reporting its color-coded COVID-19 Community Levels, switching to tracking hospitalizations in some areas. Hospitalizations, however, are a lagging indicator, as it takes about a week to 10 days for a person to be hospitalized with a serious infection. Additionally, most states have stopped public reporting of COVID-19 cases and related deaths, or stopped surveillance efforts altogether, leaving little information to enable scientists to determine how the virus is trending. While most feel the nation, and the world, has moved beyond the days of massive case surges and overwhelmed hospitals, the new normal remains unknown but likely will entail a series of smaller “wavelets.” The virus’s evolution remains unpredictable, however, and without better surveillance, experts are unable to say whether this period of the lowest levels of reported cases and deaths since the beginning of the pandemic is the beginning of a post-pandemic stability or a temporary reprieve.

A panel of global health experts is meeting today to discuss whether COVID-19 still constitutes a public health emergency of international concern (PHEIC). Although there is no consensus on what course the panel may recommend, and whether WHO Director-General Dr. Tedros Adhanom Ghebreyesus follows that advice, several experts feel it is time to wind down the emergency declaration. Regardless of its decision, COVID-19 will remain a complex public health challenge into the future, requiring countries to transition their emergency response activities to longer-term sustained disease prevention, control, and management.

Experts begin to assess pandemic responses, glean lessons learned to prepare for next pandemic

As the COVID-19 public health emergency comes to an end in the US, health officials are working to assess the nation’s response to the COVID-19 pandemic and ensure we are prepared for future health emergencies. In one such effort, 34 experts who were gearing up for the establishment of a 9/11-style commission instead formed the COVID Crisis Group, led by Dr. Philip Zelikow. When the call to establish a National COVID Commission never came, the group pivoted to develop a nonpartisan, dispassionate review of the pandemic response, which was often marred by politicization and infighting. In a report titled, Lessons from the COVID War: An Investigative Report—published by PublicAffairs as a book—the authors outline what went right and wrong with the pandemic response, including why people made certain choices, the availability of information necessary for decision makers to make choices, and the tools that were available and those that necessitated development.

The report includes information from interviews with nearly 300 people and often compares the pandemic response to a military conflict, saying the efforts in the US unraveled like fighting a war with no army or battle plan. According to the report, a lack of human coordination due to a fragmented US public health system, rather than scientific limitations, was one of the major points of failure in the response. Another major lesson centers around communication, with the report highlighting overall emergency communications as a point of failure, during both the Trump and Biden administrations. Poor communication likely exacerbated a loss of trust in US public health institutions, according to the authors. Notably, however, efforts that reached out to local community leaders were often more successful, and future responses will need practical toolkits to aid decision makers in implementing effective communications and mitigation efforts.

The European Centre for Disease Prevention and Control (ECDC) this week published its own assessment of its pandemic response. The report, titled Lessons from the COVID-19 Pandemic, contains 4 main lesson areas: investment in the public health workforce, preparation for the next public health crisis, risk communication and community engagement, and collection and analysis of data and evidence. The collection of pandemic response lessons and recommendations is a crucial task, but political buy-in is needed to implement many of the changes recommended by these assessments that are necessary for preventing and responding to the next pandemic.

Journal articles review progress made, lessons learned on COVID-19 treatment; studies into new treatments, repurposed drugs continue

The journals Nature Reviews Drug Discovery and The BMJ recently published articles examining therapeutic strategies for COVID-19, including progress made, lessons learned, and global standard of care development. Authorized or approved therapies that reduce mortality, length of hospital stay, or time on a ventilator for patients with severe disease include systemic corticosteroids (such as dexamethasone), interleukin-6 receptor antagonists (such as tocilizumab), and Janus kinase inhibitors (such as baricitinib). Additionally, marketed antivirals, including molnupiravir (Lagevrio), nirmatrelvir/ritonavir (Paxlovid), and remdesivir (Veklury), are effective against non-severe COVID-19, particularly when given within 10 days of symptom onset. More than 400 randomized clinical trials have been conducted worldwide on treatments for COVID-19, and research into new therapies continues.

  • A study published in the Annals of Internal Medicine evaluated the use of 2 repurposed drugs, the oral selective serotonin reuptake inhibitor (SSRI) fluvoxamine plus the inhaled corticosteroid budesonide, among nonhospitalized adults with early symptomatic COVID-19 and at least one risk factor for severe disease in Brazil. Though a lower proportion of patients in the treatment group than in the placebo group were seen in an emergency setting for COVID-19 for more than 6 hours or were hospitalized within 28 days, no differences were noted in secondary outcomes. 
  • Another study published in the Annals of Internal Medicine assessed the safety and efficacy of the monoclonal antibodies amubarvimab plus romlusevimab among patients at high risk for poor outcomes in the US, Brazil, South Africa, Mexico, Argentina, and the Philippines during the first half of 2021. Cumulative incidence of hospitalization or death was significantly lower in the treatment group than in the placebo group, regardless of treatment timing. A subgroup analysis of patients with variant data showed the combination was equally effective against Delta and pre-Delta strains, but the researchers speculated the therapy likely would have limited efficacy against the currently predominant Omicron variant.

Vaccine effectiveness studies support use of bivalent formulations, show monovalent vaccines highly effective against severe disease, death but effectiveness waned quickly against Omicron

Advisors to the US FDA are scheduled to meet on June 15 to discuss and make recommendations on future vaccinations against COVID-19 for the general public, now that a second round of bivalent boosters is available for older adults and other people at high risk of severe disease. The FDA will make decisions after the panel meets, but officials previously indicated a desire to recommend annual shots that are possibly updated to match currently circulating variants, similar to flu vaccines. In a study published in Open Forum Infectious Diseases, researchers report that the effectiveness of both Omicron BA.1-containing and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic infection during the BA.5-dominant period in Japan was high compared to no vaccination (65% and 76%, respectively) and moderate compared to monovalent vaccines administered over half a year earlier (46% combined). Notably, however, the bivalent vaccines were not as effective against Omicron subvariants as the original, monovalent vaccines were against the ancestral strain (Alpha) and Delta variants.

Though the monovalent mRNA vaccines are no longer authorized for use in the US, having been replaced by the bivalent versions, several recent studies show they provided substantial, durable protection against severe COVID-19 disease and death. A study published last week in Morbidity and Mortality Weekly Report found monovalent mRNA vaccination was 76% effective in preventing COVID-19-associated invasive mechanical ventilation (IMV) and death less than 6 months after the last dose and remained 56% effective at 1–2 years. Vaccine effectiveness was higher among older adults, supporting optional, additional bivalent boosters for individuals at highest risk of severe disease. A meta-analysis published in JAMA Network Open shows that vaccine effectiveness of the monovalent vaccines waned quickly and significantly against laboratory-confirmed Omicron infection and symptomatic disease, although the type of vaccine played some role. These studies support the use of updated, bivalent mRNA vaccines and boosters moving forward, and provide some evidence for reformulating the vaccines to match future dominant variants.

Decreasing US racial disparities in COVID-19 deaths possibly due to more deaths among Whites, study shows

A study published this week in JAMA Network Open examines the factors driving changes in mortality rate disparities among racial and ethnic groups over the course of the COVID-19 pandemic. Mortality rates for Hispanic and non-Hispanic Black US residents were much higher than mortality rates for non-Hispanic White residents during the initial wave of the pandemic in 2020. However, those mortality rate disparities decreased in 2021. According to the study, 60.3% of the decrease in mortality disparities are attributable to higher mortality among non-Hispanic White adults and a shift in higher mortality rates to nonmetropolitan areas, where more non-Hispanic White adults reside. The findings highlight a continued need to prioritize racial health equity despite recent reports of decreased mortality disparities, according to the authors, who also make several policy recommendations that could address health equity, including: paid medical leave for essential workers, extended unemployment benefits, and further moratoriums on eviction and foreclosure.

The Kaiser Family Foundation recently released a brief examining the impact of the COVID-19 pandemic by race and ethnicity through the lens of premature mortality, using the measures of premature mortality rate and years of life lost among excess deaths that occurred during the pandemic. The analysis shows that for all groups of color, the pandemic was associated with a steeper increase in the premature death rate than for White people. Notably, the increase in the premature death rate for Hispanic people (33%) was more than twice that of White people (14%) from 2019 to 2022.

What we’re reading

HEALTH SYSTEM RECOVERY According to a new interim report from the WHO, health systems in many countries are beginning to show the first major signs of recovery after 3 years of the COVID-19 pandemic. By early 2023, most countries reported experiencing reduced disruptions in the delivery of routine health services but highlighted the need to apply lessons learned to build more prepared and resilient health systems for the future, according to the report. Despite signs of recovery, service disruptions persist across countries in all regions and income levels, and additional support is needed for recovery, resilience, and preparedness.

US CDC CONFERENCE OUTBREAK The US CDC is investigating several dozen COVID-19 cases linked to its own annual conference held near the agency’s headquarters in Atlanta, Georgia, last week. About 35 people have tested positive as of May 2, according to a CDC spokesperson. The 3-day 2023 Epidemic Intelligence Service conference was the first time in 4 years that EIS officers and alumni gathered in-person. Around 2,000 people attended the conference, and while attendees said many people at the conference did not wear masks or socially distance, most were likely fully vaccinated. The CDC is working with state health officials to determine transmission patterns. The outbreak serves as a reminder that while COVID-19 may not pose the serious risks it did at the beginning of the pandemic, the virus continues to circulate, maybe especially easily at large indoor gatherings.

IVERMECTIN The Wisconsin Supreme Court this week ruled that a hospital cannot be forced to administer ivermectin to a COVID-19 patient. The 6-1 ruling overturned a lower court's order that required Aurora Health Care to treat John Zingsheim, who was placed on a ventilator due to COVID-19 complications, with the anti-parasitic medication. Zingsheim's nephew, Allen Gahl, who was authorized to make medical decisions for Zingsheim, requested his uncle be treated with the drug, but Aurora determined that ivermectin did not meet the standard of care for treating Zingsheim's symptoms. Gahl then sued after doctors refused to administer a prescription for ivermectin that he received from a doctor outside Aurora. The court found that the lower court had no legal basis for its order, citing no law in either its written or oral ruling. The FDA has not approved ivermectin for the treatment of COVID-19, and its misuse can be harmful, even fatal. The lawsuit is one of dozens filed across the US seeking to force hospitals to administer ivermectin to treat COVID-19.

BRAZIL INVESTIGATION Brazil's federal police on May 3 raided the home of former President Jair Bolsonaro as part of an investigation into the alleged falsification of COVID-19 vaccine cards. Authorities seized his phone, searched more than a dozen homes in Rio de Janeiro and Brasília, and arrested 6 people, including some of Bolsonaro’s closest aides. In a statement, the police said the investigation is focused on whether officials in Bolsonaro's inner circle created false vaccination certificates so that unvaccinated travelers, including Bolsonaro, his family members, and assistants' relatives, could circumvent mandatory immunization requirements to enter the US. Bolsonaro confirmed to reporters that he is not vaccinated against COVID-19 but denied playing a role in any fraud.

Epi update

As of May 3, the WHO COVID-19 Dashboard reports:

  • 765.2 million cumulative COVID-19 cases
  • 6.9 million deaths
  • 630,979 million cases reported week of April 24
  • 15% decrease in global weekly incidence
  • 3,568 deaths reported week of April 24
  • 18% decrease in global weekly mortality

Over the previous week, incidence declined or remained relatively stable in all regions except Africa (+17%).

UNITED STATES

The US CDC is reporting:

  • 104.5 million cumulative cases
  • 1.13 million deaths
  • 88,330 cases week of April 26 (down from previous week)
  • 1,052 deaths week of April 26 (down from previous week)
  • 13.7% weekly decrease in new hospital admissions
  • 15.2% weekly decrease in current hospitalizations

The Omicron sublineages XBB.1.5 (69%), XBB.1.16 (12%), XBB.1.9.1 (69%), XBB.1.9.2 (4%), XBB (2.4%), XBB.1.5.1 (2.2%), and FD.2 (1.3%) currently account for a majority of all new sequenced specimens, with various other Omicron subvariants accounting for the remainder of cases.

Editor: Alyson Browett, MPH

Contributors: Erin Fink, MS; Clint Haines, MS; Amanda Kobokovich, MPH; Aishwarya Nagar, MPH; Christina Potter, MSPH; Matthew Shearer, MPH; and Rachel A. Vahey, MH